Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice

Cancer Immunology, Immunotherapy

Volumn 61, Issue 5, 2012, Pages 643-654

  Hamilton, Melisa J ^a   Banáth, Judit P ^b   Lam, Vivian ^a   LePard, Nancy E ^b   Krystal, Gerald ^a   Bennewith, Kevin L ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

4T1 tumor cells; Albumin; Immune suppression; Myeloid derived suppressor cells (MDSCs); Serum

Indexed keywords

BOVINE SERUM ALBUMIN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELLULAR DISTRIBUTION; CELLULAR IMMUNITY; CONTROLLED STUDY; CULTURE MEDIUM; EX VIVO STUDY; FEMALE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LUNG; LYMPHOCYTE PROLIFERATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE STUDY; SERUM; SPLEEN; SUPPRESSOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; CATTLE; CELL CULTURE TECHNIQUES; CELL GROWTH PROCESSES; FEMALE; IMMUNOSUPPRESSION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MYELOID CELLS; REACTIVE OXYGEN SPECIES; SERUM ALBUMIN, BOVINE; T-LYMPHOCYTES;

EID: 84862496594     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1125-0     Document Type: Article

References (43)

1. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ (2008) Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 84:988-993
2. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3-15
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646-674
4. Biswas SK, Mantovani A (2010) Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11:889-896
5. Nagaraj S, Gabrilovich DI (2010) Myeloid-derived suppressor cells in human cancer. Cancer J 16:348-353
6. Youn JI, Gabrilovich DI (2010) The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol 40:2969-2975
7. Priceman SJ, Sung JL, Shaposhnik Z, Burton JB, Torres-Collado AX, Moughon DL, Johnson M, Lusis AJ, Cohen DA, Iruela- Arispe ML, Wu L (2010) Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115:1461-1471
8. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC (2004) Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6:409-421 (Pubitemid 39361441)
9. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, Moses HL (2008) Abrogation of TGF β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13:23-35 (Pubitemid 350309741)
10. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Interleukin- 13-regulated M2 macrophages in combination with myeloid suppressor cells block immune surveillance against metastasis. Cancer Res 65:11743-11751 (Pubitemid 41821736)
11. Ostrand-Rosenberg S (2010) Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 59:1593-1600
12. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, Yancey D, Dahm P, Vieweg J (2008) Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14:8270-8278
13. Vieweg J, Su Z, Dahm P, Kusmartsev S (2007) Reversal of tumor-mediated immunosuppression. Clin Cancer Res 13:727s-732s
14. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65:3044-3048 (Pubitemid 40524582)
15. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC (2007) Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13:721s-726s
16. Young MR, Lathers DM (1999) Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J Immunopharmacol 21:241-252 (Pubitemid 29241776)
17. + myeloid-derived suppressor cell expansion in cancer patients. J Immunol 182:6562-6568
18. Valenti R, Huber V, Filipazzi P, Pilla L, Sovena G, Villa A, Corbelli A, Fais S, Parmiani G, Rivoltini L (2006) Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-β-mediated suppressive activity on T lymphocytes. Cancer Res 66:9290-9298 (Pubitemid 44521151)
19. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ (2009) Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58:49-59
20. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI (2008) Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181:5791-5802
21. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC (2005) Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202:931-939 (Pubitemid 41396893)
22. Gallina G, Dolcetti L, Serafini P, De Santo C, Marigo I, Colombo MP, Basso G, Brombacher F, Borrello I, Zanovello P, Bicciato S, Bronte V (2006) Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116:2777-2790 (Pubitemid 44511641)
23. Habibi M, Kmieciak M, Graham L, Morales JK, Bear HD, Manjili MH (2009) Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat 114:423-431
24. Greenwald RJ, Freeman GJ, Sharpe AH (2005) The B7 family revisited. Annu Rev Immunol 23:515-548 (Pubitemid 40563179)
25. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W (2006) B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 203:871-881
26. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66:1123-1131
27. Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52:1399-1405
28. Pulaski BA, Ostrand-Rosenberg S (2001) Mouse 4T1 breast tumor model. Curr Protoc Immunol Chap 20:Unit 20.2
29. Heppner GH, Miller FR, Shekhar PM (2000) Nontransgenic models of breast cancer. Breast Cancer Res 2:331-334 (Pubitemid 32223615)
30. Sinha P, Clements VK, Ostrand-Rosenberg S (2005) Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174:636-645 (Pubitemid 40094255)
31. Ko JS, Rayman P, Ireland J, Swaidani S, Li G, Bunting KD, Rini B, Finke JH, Cohen PA (2010) Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 70:3526-3536
32. Srivastava MK, Sinha P, Clements VK, Rodriguez P, Ostrand- Rosenberg S (2010) Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70:68-77
33. Murphy KM, Heimberger AB, Loh DY (1990) Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlo thymocytes in vivo. Science 250:1720-1723 (Pubitemid 120031881)
34. Le HK, Graham L, Cha E, Morales JK, Manjili MH, Bear HD (2009) Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. Int Immunopharmacol 9:900-909
35. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY (2010) A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 16:4583-4594
36. Seifert CF, Resman-Targoff BH (2006) Clinical laboratory tests and interpretation. In: Helms RA, Quan DJ, Herfindal ET, Gourley DR (eds) Textbook of therapeutics: drug and disease management. Lippincott Williams & Wilkins, Philadelphia, pp 91-115
37. Monette FC, Sigounas G (1990) Some observations on the growth requirements of multi-potent stem cells under defined culture conditions. In: Dainiak N, Cronkite EP, McCaffrey R, Shadduck RK (eds) The biology of hematopoiesis. Wiley-Liss, Inc., New York, pp 37-48
38. Chen HW, Kandutsch AA (1981) Cholesterol requirements for cell growth: endogenous synthesis versus exogenous sources. In: Weymouth C, Ham RG, Chapple PJ (eds) The growth requirements of vertebrate cells in vitro. Cambridge University Press, New York, pp 327-342
39. Barnes D, Sato G (1980) Serum-free cell culture: a unifying approach. Cell 22:649-655 (Pubitemid 11218753)
40. Dainiak N (1985) Role of defined and undefined serum additives to hematopoietic stem cell culture. In: Cronkite EP, Dainiak N, McCaffrey RP, Palek J, Quesenberry PJ (eds) Hematopoietic stem cell physiology. Alan R. Liss, New York, pp 59-76
41. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G (2008) Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181:4666-4675
42. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL (2011) In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol 41:749-759
43. Nausch N, Galani IE, Schlecker E, Cerwenka A (2008) Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood 112:4080-4089